Astellas and Theravance Report Additional Telavancin Data at 47th An...(Antimicrobial Activity of Telavancin aga...)

and Streptococci: Initial results from a Global Surveillance Program

This study was designed to examine the activity of telavancin against

both enterococci and streptococci pathogens versus the commonly used

drugs vancomycin, levofloxacin, daptomycin, linezolid and

quinupristin/dalfopristin. In the more than 2,700 clinical isolates

tested, telavancin was one of the most potent agents. When evaluated

in light of other data on bactericidal effect in staphylococci

infections, the totality of data suggest clinical activity across the

range of Gram-positive bacteria.

About ATLAS

The ATLAS studies were two separate but identical, randomized, double-blind trials to evaluate the efficacy and safety of telavancin versus vancomycin in patients with cSSSIs, especially those due to MRSA. In the ATLAS studies, telavancin contained the largest subset of patients over 18 years old with surgical-site associated cSSSIs of any randomized, double-blind study to date. The most common adverse events reported in patients receiving telavancin were mild to moderate taste disturbance and nausea. In addition, consistent with previous studies, small percentages of telavancin-treated patients experienced renal adverse events or increases in the QTc interval. In ATLAS, the most commonly reported (>10%) adverse events in patients treated with telavancin were taste disturbance, nausea, vomiting, headache, and foamy urine.

MRSA: A Growing Global Epidemic

An estimated 1.2 million hospitalized patients in the United States may be infected with MRSA, a type of bacteria that is resistant to antibiotics commonly used to treat staphylococci infections. In the healthcare setting, the proportion of resistant infections has grown. In 2004, according to the Centers for Disease Control (CDC), MRSA infections accounted for a
'/>"/>